TABLE 1.
Demographic and clinical characteristics of children with cancer diagnosed with SARS‐CoV‐2 infection in Greece (n = 15)
| N | Sex | Age (years) at COVID‐19 diagnosis | Age (years) at cancer diagnosis | Type of cancer | Treatment for cancer or F/U | COVID‐19 symptoms at diagnosis | Source of infection | Cancer treatment modification | Hospitalization for COVID‐19 | Antimicrobials |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 14.1 | 12.5 | HL | F/U | Fever | Family | N/A | No | AZ |
| 2 | F | 5.9 | 0.7 | CNS‐T | M/A | Tracing | Parents | Withheld | No | AZ |
| 3 | F | 8.8 | 7.5 | ALL | MT | Tracing | Parents | Withheld | No | AZ |
| 4 | M | 9.8 | 7.9 | ALL | MT | Sore throat | Parents | Withheld | No | – |
| 5 | M | 5.6 | 3.9 | ALL | MT | Tracing | Parents | Withheld | No | – |
| 6 | F | 15.2 | 14.4 | OS | RT | Fever | Sibling | Withheld | No | – |
| 7 | M | 14.4 | 12.7 | NHL | F/U | Fever | Family | Ν/Α | No | – |
| 8 | F | 10.5 | 8.5 | NHL | MT | Fever | Father | Withheld | No | – |
| 9 | M | 14.3 | 9.3 | HL | F/U | Fever | Family | N/A | No | – |
| 10 | M | 5.9 | 3.9 | ALL | MT | Tracing | Family | Withheld | No | – |
| 11 | F | 18.6 | 12.9 | ALL | F/U | Tracing | Family | N/A | No | – |
| 12 | F | 5.7 | 3.3 | ALL | F/U | Fever | Grandfather | N/A | No | – |
| 13 | M | 17.3 | 0.4 | NB | F/U | Anosmia | Family | N/A | No | – |
| 14 | F | 9.4 | 7.7 | CNS‐T | F/U | Fever | Aunt | N/A | No | – |
| 15 | F | 4.9 | 4.3 | ALL | A/R <30 days | Fever | Unknown | N/A | Yes (4 days) | Pip‐Taz |
Abbreviations: ALL, acute lymphoblastic leukemia; A/R, after reinduction; AZ, azithromycin; CNS‐T, central nervous system tumor; F/U, follow up; HL, Hodgkins lymphoma; M/A, monoclonal antibody; MT, maintenance; Ν/Α, not applicable; NB, neuroblastoma; NHL, non‐Hodgkins lymphoma; OS, osteosarcoma; Pip‐Taz, piperacillin‐tazobactam; RT, radiotherapy.